Inhibition of p38α MAPK disrupts the pathological loop of proinflammatory factor production in the myelodysplastic syndrome bone marrow microenvironment

References

• Greenberg P, Cox C, LeBeau M M, Fenaux P, Morel P, Sanz G, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997; 89: 2079–88
   PubMed Web of Science ®Google Scholar
• Heaney M L, Golde D W. Myelodysplasia. N Engl J Med 1999; 340: 1649–1660
   PubMed Web of Science ®Google Scholar
• Verma A, List A F. Cytokine targets in the treatment of myelodysplastic syndromes. Curr Hematol Rep 2005; 4: 429–435
   PubMedGoogle Scholar
• Allampallam K, Shetty V, Mundle S, Dutt D, Kravitz H, Reddy P L, et al. Biological significance of proliferation, apoptosis, cytokines, and monocyte/macrophage cells in bone marrow biopsies of 145 patients with myelodysplastic syndrome. Int J Hematol 2002; 75: 289–297
   PubMed Web of Science ®Google Scholar
• Claessens Y E, Park S, Dubart-Kupperschmitt A, Mariot V, Garrido C, Chretien S, et al. Rescue of early stage myelodysplastic syndrome-deriving erythroid precursors by the ectopic expression of a dominant negative form of FADD. Blood 2005; 105: 4035–4042
   PubMed Web of Science ®Google Scholar
• Zorat F, Shetty V, Dutt D, Lisak L, Nascimben F, Allampallam K, et al. The clinical and biological effects of thalidomide in patients with myelodysplastic syndromes. Br J Haematol 2001; 115: 881–894
   PubMed Web of Science ®Google Scholar
• Deeg H J, Beckham C, Loken M R, Bryant E, Lesnikova M, Shulman H M, et al. Negative regulators of hemopoiesis and stroma function in patients with myelodysplastic syndrome. Leuk Lymphoma 2000; 37: 405–414
   PubMed Web of Science ®Google Scholar
• Allampallam K, Shetty V, Hussaini S, Mazzoran L, Zorat F, Huang R, et al. Measurement of mRNA expression for a variety of cytokines and its receptors in bone marrows of patients with myelodysplastic syndromes. Anticancer Res 1999; 19: 5323–5328
   PubMed Web of Science ®Google Scholar
• Mundle S D, Reza S, Ali A, Mativi Y, Shetty V, Venugopal P, et al. Correlation of tumor necrosis factor alpha (TNF alpha) with high Caspase 3-like activity in myelodysplastic syndromes. Cancer Lett 1999; 140: 201–207
   PubMed Web of Science ®Google Scholar
• Dufour C, Corcione A, Svahn J, Haupt R, Battilana N, Pistoia V. Interferon gamma and tumour necrosis factor alpha are overexpressed in bone marrow T lymphocytes from paediatric patients with aplastic anaemia. Br J Haematol 2001; 115: 1023–1031
   PubMed Web of Science ®Google Scholar
• Welsh J P, Rutherford T R, Flynn J, Foukaneli T, Gordon-Smith E C, Gibson F M. In vitro effects of interferon-gamma and tumor necrosis factor-alpha on CD34+ bone marrow progenitor cells from aplastic anemia patients and normal donors. Hematol J 2004; 5: 39–46
   PubMedGoogle Scholar
• Koike M, Ishiyama T, Tomoyasu S, Tsuruoka N. Spontaneous cytokine overproduction by peripheral blood mononuclear cells from patients with myelodysplastic syndromes and aplastic anemia. Leuk Res 1995; 19: 639–644
   PubMed Web of Science ®Google Scholar
• Dufour C, Corcione A, Svahn J, Haupt R, Poggi V, Beka'ssy A N, et al. TNF-alpha and IFN-gamma are overexpressed in the bone marrow of Fanconi anemia patients and TNF-alpha suppresses erythropoiesis in vitro. Blood 2003; 102: 2053–2059
   PubMed Web of Science ®Google Scholar
• Kitagawa M, Saito I, Kuwata T, Yoshida S, Yamaguchi S, Takahashi M, Tanizawa T, Kamiyama R, Hirokawa K. Overexpression of tumor necrosis factor (TNF)-alpha and interferon (IFN)-gamma by bone marrow cells from patients with myelodysplastic syndromes. Leukemia 1997; 11: 2049–2054
   PubMed Web of Science ®Google Scholar
• Bellamy W T, Richter L, Sirjani D, Roxas C, Glinsmann-Gibson B, Frutiger Y, et al. Vascular endothelial cell growth factor is an autocrine promoter of abnormal localized immature myeloid precursors and leukemia progenitor formation in myelodysplastic syndromes. Blood 2001; 97: 1427–1434
   PubMed Web of Science ®Google Scholar
• Gabrilovich D, Ishida T, Oyama T, Ran S, Kravtsov V, Nadaf S, et al. Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo. Blood 1998; 92: 4150–4166
   PubMed Web of Science ®Google Scholar
• Aguayo A, Kantarjian H, Manshouri T, Gidel C, Estey E, Thomas D, et al. Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes. Blood 2000; 96: 2240–2245
   PubMed Web of Science ®Google Scholar
• Kurzrock R, Kantarjian H, Wetzler M, Estrov Z, Estey E, Troutman-Worden K, et al. Ubiquitous expression of cytokines in diverse leukemias of lymphoid and myeloid lineage. Exp Hematol 1993; 21: 80–85
   PubMed Web of Science ®Google Scholar
• Griffin J D, Rambaldi A, Vellenga E, Young D C, Ostapovicz D, Cannistra S A. Secretion of interleukin-1 by acute myeloblastic leukemia cells in vitro induces endothelial cells to secrete colony stimulating factors. Blood 1987; 70: 1218–1221
   PubMed Web of Science ®Google Scholar
• Dinarello C A. Biologic basis for interleukin-1 in disease. Blood 1996; 87: 2095–2147
   PubMed Web of Science ®Google Scholar
• Bagby Jr. GC. Interleukin-1 and hematopoiesis. Blood Rev 1989; 3: 152–161
   PubMed Web of Science ®Google Scholar
• Grigorieva I, Thomas X, Epstein J. The bone marrow stromal environment is a major factor in myeloma cell resistance to dexamethasone. Exp Hematol 1998; 26: 597–603
   PubMed Web of Science ®Google Scholar
• Yasui H, Hideshima T, Richardson P G, Anderson K C. Novel therapeutic strategies targeting growth factor signalling cascades in multiple myeloma. Br J Haematol 2006; 132: 385–397
   PubMed Web of Science ®Google Scholar
• Tefferi A. Myelofibrosis with myeloid metaplasia. N Engl J Med 2000; 342: 1255–1265
   PubMed Web of Science ®Google Scholar
• Flores-Figueroa E, Arana-Trejo R M, Gutierrez-Espindola G, Perez-Cabrera A, Mayani H. Mesenchymal stem cells in myelodysplastic syndromes: phenotypic and cytogenetic characterization. Leuk Res 2005; 29: 215–224
   PubMed Web of Science ®Google Scholar
• Narendran A, Hawkins L M, Ganjavi H, Vanek W, Gee M F, Barlow J W, et al. Characterization of bone marrow stromal abnormalities in a patient with constitutional trisomy 8 mosaicism and myelodysplastic syndrome. Pediatr Hematol Oncol 2004; 21: 209–221
   PubMed Web of Science ®Google Scholar
• Tauro S, Hepburn M D, Bowen D T, Pippard M J. Assessment of stromal function, and its potential contribution to deregulation of hematopoiesis in the myelodysplastic syndromes. Haematologica 2001; 86: 1038–1045
   PubMed Web of Science ®Google Scholar
• Aizawa S, Nakano M, Iwase O, Yaguchi M, Hiramoto M, Hoshi H, et al. Bone marrow stroma from refractory anemia of myelodysplastic syndrome is defective in its ability to support normal CD34-positive cell proliferation and differentiation in vitro. Leuk Res 1999; 23: 239–246
   PubMed Web of Science ®Google Scholar
• Deeg H J. Marrow stroma in MDS: culprit or bystander?. Leuk Res 2002; 26: 687–688
   PubMed Web of Science ®Google Scholar
• Aizawa S, Hiramoto M, Hoshi H, Toyama K, Shima D, Handa H. Establishment of stromal cell line from an MDS RA patient which induced an apoptotic change in hematopoietic and leukemic cells in vitro. Exp Hematol 2000; 28: 148–155
   PubMed Web of Science ®Google Scholar
• Young N S, Maciejewski J. The pathophysiology of acquired aplastic anemia. N Engl J Med 1997; 336: 1365–1372
   PubMed Web of Science ®Google Scholar
• Kook H, Zeng W, Guibin C, Kirby M, Young N S, Maciejewski J P. Increased cytotoxic T cells with effector phenotype in aplastic anemia and myelodysplasia. Exp Hematol 2001; 29: 1270–1277
   PubMed Web of Science ®Google Scholar
• Selleri C, Maciejewski J P, Catalano L, Ricci P, Andretta C, Luciano L, et al. Effects of cyclosporine on hematopoietic and immune functions in patients with hypoplastic myelodysplasia: in vitro and in vivo studies. Cancer 2002; 95: 1911–1922
   PubMed Web of Science ®Google Scholar
• Sloand E M, Mainwaring L, Fuhrer M, Ramkissoon S, Risitano A M, Keyvanafar K, et al. Preferential suppression of trisomy 8 compared with normal hematopoietic cell growth by autologous lymphocytes in patients with trisomy 8 myelodysplastic syndrome. Blood 2005; 106: 841–851
   PubMed Web of Science ®Google Scholar
• Sloand E M, Pfannes L, Chen G, Shah S, Solomou E E, Barrett J, et al. CD34 cells from patients with trisomy 8 myelodysplastic syndrome (MDS) express early apoptotic markers but avoid programmed cell death by up-regulation of antiapoptotic proteins. Blood 2007; 109: 2399–2405
   PubMed Web of Science ®Google Scholar
• Johnson G L, Lapadat R. Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science 2002; 298: 1911–1912
   PubMed Web of Science ®Google Scholar
• Kumar S, Boehm J, Lee J C. p38 MAP kinases: key signalling molecules as therapeutic targets for inflammatory diseases. Nat Rev Drug Discov 2003; 2: 717–726
   PubMed Web of Science ®Google Scholar
• Platanias L C. Map kinase signaling pathways and hematologic malignancies. Blood 2003; 101: 4667–4679
   PubMed Web of Science ®Google Scholar
• Navas T A, Mohindru M, Estes M, Ma J Y, Sokol L, Pahanish P, et al. Inhibition of overactivated p38 MAPK can restore hematopoiesis in myelodysplastic syndrome progenitors. Blood 2006; 108: 4170–4177
   PubMed Web of Science ®Google Scholar
• Navas T A, Nguyen A N, Hideshima T, Reddy M, Ma J Y, Haghnazari E, et al. Inhibition of p38alpha MAPK enhances proteasome inhibitor-induced apoptosis of myeloma cells by modulating Hsp27, Bcl-X(L), Mcl-1 and p53 levels in vitro and inhibits tumor growth in vivo. Leukemia 2006; 20: 1017–1027
   PubMed Web of Science ®Google Scholar
• Verma A, Deb D K, Sassano A, Kambhampati S, Wickrema A, Uddin S, et al. Cutting edge: activation of the p38 mitogen-activated protein kinase signaling pathway mediates cytokine-induced hemopoietic suppression in aplastic anemia. J Immunol 2002; 168: 5984–5988
   PubMed Web of Science ®Google Scholar
• Mohindru M, Kang B, Kim B S. Initial capsid-specific CD4(+) T cell responses protect against Theiler's murine encephalomyelitisvirus-induced demyelinating disease. Eur J Immunol 2006; 36: 2106–2115
   PubMed Web of Science ®Google Scholar
• Kapoun A M, Liang F, O'Young G, Damm D L, Quon D, White R T, et al. B-type natriuretic peptide exerts broad functional opposition to transforming growth factor-beta in primary human cardiac fibroblasts: fibrosis, myofibroblast conversion, proliferation, and inflammation. Circ Res 2004; 94: 453–461
   PubMed Web of Science ®Google Scholar
• Nguyen A N, Stebbins E G, Henson M, O'Young G, Choi S J, Quon D, et al. Normalizing the bone marrow microenvironment with p38 inhibitor reduces multiple myeloma cell proliferation and adhesion and suppresses osteoclast formation. Exp Cell Res 2006; 312: 1909–1923
   PubMed Web of Science ®Google Scholar
• Haneline L S, Broxmeyer H E, Cooper S, Hangoc G, Carreau M, Buchwald M, et al. Multiple inhibitory cytokines induce deregulated progenitor growth and apoptosis in hematopoietic cells from Fac−/− mice. Blood 1998; 91: 4092–4098
   PubMed Web of Science ®Google Scholar
• Devine S M, Flomenberg N, Vesole D H, Liesveld J, Weisdorf D, Badel K, et al. Rapid mobilization of CD34+ cells following administration of the CXCR4 antagonist AMD3100 to patients with multiple myeloma and non-Hodgkin's lymphoma. J Clin Oncol 2004; 22: 1095–1102
   PubMed Web of Science ®Google Scholar
• List A F. Vascular endothelial growth factor signaling pathway as an emerging target in hematologic malignancies. Oncologist 2001; 6(Suppl 5)24–31
   PubMed Web of Science ®Google Scholar
• Nath P, Leung S Y, Williams A, Noble A, Chakravarty S D, Luedtke G R, et al. Importance of p38 mitogen-activated protein kinase pathway in allergic airway remodelling and bronchial hyperresponsiveness. Eur J Pharmacol 2006; 544: 160–167
   PubMed Web of Science ®Google Scholar
• Verma A, Deb D K, Sassano A, Uddin S, Varga J, Wickrema A, et al. Activation of the p38 mitogen-activated protein kinase mediates the suppressive effects of type I interferons and transforming growth factor-beta on normal hematopoiesis. J Biol Chem 2002; 277: 7726–7735
   PubMed Web of Science ®Google Scholar
• Means Jr. RT, Dessypris E N, Krantz S B. Inhibition of human erythroid colony-forming units by interleukin-1 is mediated by gamma interferon. J Cell Physiol 1992; 150: 59–64
   PubMed Web of Science ®Google Scholar
• Jelkmann W, Wolff M, Fandrey J. Modulation of the production of erythropoietin by cytokines: in vitro studies and their clinical implications. Contrib Nephrol 1990; 87: 68–77
   PubMedGoogle Scholar
• Werner S L, Barken D, Hoffmann A. Stimulus specificity of gene expression programs determined by temporal control of IKK activity. Science 2005; 309: 1857–1861
   PubMed Web of Science ®Google Scholar
• Brinkman B M, Telliez J B, Schievella A R, Lin L L, Goldfeld A E. Engagement of tumor necrosis factor (TNF) receptor 1 leads to ATF-2- and p38 mitogen-activated protein kinase-dependent TNF-alpha gene expression. J Biol Chem 1999; 274: 30882–30886
   PubMed Web of Science ®Google Scholar
• Kotlyarov A, Neininger A, Schubert C, Eckert R, Birchmeier C, Volk H D, et al. MAPKAP kinase 2 is essential for LPS-induced TNF-alpha biosynthesis. Nat Cell Biol 1999; 1: 94–97
   PubMed Web of Science ®Google Scholar
• Legare R D, Gilliland D G. Myelodysplastic syndrome. Curr Opin Hematol 1995; 2: 283–292
   PubMedGoogle Scholar
• Greenberg P L. Apoptosis and its role in the myelodysplastic syndromes: implications for disease natural history and treatment. Leuk Res 1998; 22: 1123–1136
   PubMed Web of Science ®Google Scholar
• List A, Dewald G, Bennett J, Giagounidis A, Raza A, Feldman E, et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med 2006; 355: 1456–1465
   PubMed Web of Science ®Google Scholar
• List A, Kurtin S, Roe D J, Buresh A, Mahadevan D, Fuchs D, et al. Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med 2005; 352: 549–557
   PubMed Web of Science ®Google Scholar
• Tai Y T, Li X F, Catley L, Coffey R, Breitkreutz I, Bae J, et al. Immunomodulatory drug lenalidomide (CC-5013, IMiD3) augments anti-CD40 SGN-40-induced cytotoxicity in human multiple myeloma: clinical implications. Cancer Res 2005; 65: 11712–11720
   PubMed Web of Science ®Google Scholar
• Anderson K C. Lenalidomide and thalidomide: mechanisms of action – similarities and differences. Semin Hematol 2005; 42: S3–S8
   PubMed Web of Science ®Google Scholar
• Sokol L, Cripe L, Kantarjian H, Sekeres M, Parmar S, Greenberg P, et al. Phase I/II, Randomized, MultiCenter MultiCenter, Dose, Dose-Ascension Study of the p38 MAPK inhibitor Ascension Study of the p38 MAPK inhibitor Scio-469 in Patients with Myelodysplastic Syndromes (MDS) 469 in Patients with Myelodysplastic Syndromes (MDS). Am Soc Hematol 2006; 108: 2657
   Google Scholar
• Raza A, Candoni A, Khan U, Lisak L, Tahir S, Silvestri F, et al. Remicade as TNF suppressor in patients with myelodysplastic syndromes. Leuk Lymphoma 2004; 45: 2099–2104
   PubMed Web of Science ®Google Scholar